References
- Alvarez Argote J, Dasanu C. ASXL1 mutations in myeloid neoplasms: pathogenetic considerations, impact on clinical outcomes and survival. Curr Med Res Opin 2017. doi: 10.1080/03007995.2016.1276896
- Katoh M. Functional and cancer genomics of ASXL family members. Br J Cancer 2013;109:299-306
- Park U-H, Yoon SK, Park T, et al. Additional sex comb-like (ASXL) proteins 1 and 2 play opposite roles in adipogenesis via reciprocal regulation of peroxisome proliferator-activated receptor γ. J Biol Chem 2011;286:1354-63
- Mcginley AL, Li Y, Deliu Z, et al. Additional sex combs-like family genes are required for normal cardiovascular development. Genesis 2014;52:671-86
- Izawa T, Rohatgi N, Fukunaga T, et al. ASXL2 regulates glucose, lipid, and skeletal homeostasis. Cell Rep 2015;11:1625-37
- Shashi V, Pena LDM, Kim K, et al. De novo truncating variants in ASXL2 are associated with a unique and recognizable clinical phenotype. Am J Hum Genet 2016;99:991-9
- Shiba N, Yoshida K, Shiraishi Y, et al. Whole-exome sequencing reveals the spectrum of gene mutations and the clonal evolution patterns in paediatric acute myeloid leukaemia. Br J Haematol 2016;175:476-89
- Huether R, Dong L, Chen X, et al. The landscape of somatic mutations in epigenetic regulators across 1,000 paediatric cancer genomes. Nat Commun 2014;5:3630
- Jahn N, Agrawal M, Bullinger L, et al. Incidence and prognostic relevance of ASXL2 mutations in adult CBF-AML with t(8;21)(q22;q22): a study of the German–Austrian AML Study Group (AMLSG). Blood 2015;126:3818
- Micol J-B, Duployez N, Boissel N, et al. Frequent ASXL2 mutations in acute myeloid leukemia patients with t(8;21)/RUNX1-RUNX1T1 chromosomal translocations. 2014;124:1445-9
- Bainbridge MN, Hu H, Muzny DM, et al. De novo truncating mutations in ASXL3 are associated with a novel clinical phenotype with similarities to Bohring–Opitz syndrome. Genome Med 2013;5:11
- Ley TJ. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 2013;368:2059-74
- Masetti R, Castelli I, Astolfi A, et al. Genomic complexity and dynamics of clonal evolution in childhood acute myeloid leukemia studied with whole-exome sequencing. Oncotarget 2016;7:56746-56757
- Duployez N, Micol J-B, Boissel N, et al. Unlike ASXL1 and ASXL2 mutations, ASXL3 mutations are rare events in acute myeloid leukemia with t(8;21). Leuk Lymphoma 2016;8211:199-200
- Gelsi-Boyer V, Trouplin V, Adélaïde J, et al. Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br J Haematol 2009;145:788-800
- Metzeler KH. ASXL genes and RUNX1: an intimate connection? Blood 2014;124:1382-3
- Pratcorona M, Abbas S, Sanders MA, et al. Acquired mutations in ASXL1 in acute myeloid leukemia: prevalence and prognostic value. Haematologica 2012;97:388-92
- Chou WC, Huang HH, Hou HA, et al. Distinct clinical and biological features of de novo acute myeloid leukemia with additional sex comb-like 1 (ASXL1) mutations. Blood 2010;116:4086-94
- Schnittger S, Eder C, Jeromin S, et al. ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome. Leukemia 2013;27:82-91
- Devillier R, Gelsi-Boyer V, Brecqueville M, et al. Acute myeloid leukemia with myelodysplasia-related changes are characterized by a specific molecular pattern with high frequency of ASXL1 mutations. Am J Hematol 2012;87:659-62
- Daou S, Hammond-Martel I, Mashtalir N, et al. The BAP1/ASXL2 histone H2A deubiquitinase complex regulates cell proliferation and is disrupted in cancer. J Biol Chem 2015;290:28643-63
- Dey A, Seshasayee D, Noubade R, et al. Loss of the tumor suppressor BAP1 causes myeloid transformation. Science 2012;337:1541-6
- Micol JB, Abdel-Wahab O. The role of additional sex combs-like proteins in cancer. Cold Spring Harb Perspect Med 2016;6:pii:a026526